No profile data available.
Werewolf Therapeutics, Inc. (HOWL) is a healthcare company in the additional cancer treatment drugs industry, based in Watertown, United States, with about 39 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$60.82 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $21.00 million. Its market capitalization was $47.61 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions.
Werewolf Therapeutics reported $0 in revenue for fiscal year 2025, down 100.0% from $1.89 million in fiscal year 2024. In Q2 2026 revenue was $21.00 million.
$47.61 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Xilio Therapeutics, Inc. (XLO), Boundless Bio, Inc. (BOLD), Elicio Therapeutics, Inc. (ELTX), Instil Bio, Inc. (TIL).